Development of a Stable-Isotope Labeled Universal Monoclonal Antibody (SILUMab) Standard

Monoclonal antibodies are increasingly becoming primary therapeutic agents for a host of human diseases. The ability to accurately assess the pharmacokinetic (PK) properties of biotherapeutics has become an essential part of monoclonal antibody development and characterization. This poster described the development and analysis of a stable-isotope-labeled universal monoclonal antibody (SILUMab) standard, which can be used as an internal standard for quantification of monoclonal antibodies as well as Fc-fusion therapeutics.